Search

Search Constraints

You searched for: Author/Creator Clemmensen, Peter

Search Results

1. Fractional Flow Reserve–Guided Complete Revascularization Improves the Prognosis in Patients With ST-Segment–Elevation Myocardial Infarction and Severe Nonculprit Disease: A DANAMI 3-PRIMULTI Substudy (Primary PCI in Patients With ST-Elevation Myocardial Infarction and Multivessel Disease. (April 2017)

2. Long-term survival and causes of death in patients with ST-elevation acute coronary syndrome without obstructive coronary artery disease. (23rd September 2017)

3. A response to a misrepresentation of the STEMI guidelines: the response. Issue 23 (19th August 2013)

4. MR‐proADM as a Prognostic Marker in Patients With ST‐Segment–Elevation Myocardial Infarction—DANAMI‐3 (a Danish Study of Optimal Acute Treatment of Patients With STEMI) Substudy. Issue 11 (18th May 2018)

5. Single-dose of adrecizumab versus placebo in acute cardiogenic shock (ACCOST-HH): an investigator-initiated, randomised, double-blinded, placebo-controlled, multicentre trial. Issue 3 (March 2022)

6. Telemedical cardiac risk assessment by implantable cardiac monitors in patients after myocardial infarction with autonomic dysfunction (SMART-MI-DZHK9): a prospective investigator-initiated, randomised, multicentre, open-label, diagnostic trial. Issue 2 (February 2022)

7. Unreported exclusion and sampling bias in interpretation of randomized controlled trials in patients with STEMI. (15th August 2019)

8. Early Stent Thrombosis and Mortality After Primary Percutaneous Coronary Intervention in ST-Segment–Elevation Myocardial Infarction: A Patient-Level Analysis of 2 Randomized Trials. (May 2016)

10. The need for PCSK9 inhibitors and associated treatment costs according to the 2019 ESC dyslipidaemia guidelines vs. the risk-based allocation algorithm of the 2017 ESC consensus statement: a simulation study in a contemporary CAD cohort. (2nd December 2020)